Rituxan (rituximab) - Roche
lncRNA CHROMR promotes DLBCL viability and invasion in an m 6A-dependent manner. (PubMed, Acta Biochim Biophys Sin (Shanghai)) - Oct 17, 2026 - "Long noncoding RNA (lncRNA) CHROMR is closely associated with the development of diffuse large B-cell lymphoma (DLBCL) and drug resistance to rituximab...Furthermore, both METTL3 and IGF2BP1 play critical roles in regulating the viability and invasion of DLBCL cells. These findings highlight the indispensable role of m 6A modification in the lncRNA CHROMR, revealing METTL3 and IGF2BP1 as epigenetic mediators that regulate CHROMR expression." 
Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • IGF2BP1 • METTL3
http://www.ncbi.nlm.nih.gov/pubmed/42886545
 
Baofeng Yu; Chan Zhang; Chang Liu; Feng Li; Hongwei Zhang; Jiahui Hou; Kun Yang; Meina Wu; Ruihan Gao; Tao Guan; Yuejing Zhao; Yurun Du
 
Oct 17, 2026
 
Prev Next